Vivos Therapeutics (VVOS)
(Delayed Data from NSDQ)
$3.44 USD
+0.10 (2.99%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $3.44 0.00 (0.00%) 4:40 PM ET
4-Sell of 5 4
F Value C Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VVOS 3.44 +0.10(2.99%)
Will VVOS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VVOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VVOS
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates
VVOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue Estimates
Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates
Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Other News for VVOS
VVOS falls 5.11% on September 19, leaving the technical picture intact
Bullish Engulfing appears for VVOS after 3.53% move
Vivos Therapeutics (VVOS) Achieves Milestone in Pediatric Sleep Apnea Treatment
Vivos Therapeutics announces trial results in pediatric OSA treatment
Vivos Therapeutics announces trial results in pediatric OSA treatment